Comparative Pharmacology
Head-to-head clinical analysis: PREVACID versus ZEGERID OTC.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PREVACID versus ZEGERID OTC.
PREVACID vs ZEGERID OTC
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Proton pump inhibitor (PPI) that irreversibly inhibits the H+/K+ ATPase enzyme (proton pump) in gastric parietal cells, thereby suppressing gastric acid secretion.
Omeprazole is a proton pump inhibitor (PPI) that suppresses gastric acid secretion by irreversibly binding to the H+/K+-ATPase enzyme (the proton pump) in the gastric parietal cells.
15-30 mg orally once daily; or 30 mg orally twice daily for severe GERD.
20 mg orally once daily before a meal for 14 days for frequent heartburn; 20 mg orally once daily for up to 8 weeks for erosive esophagitis healing; 20 mg orally once daily for maintenance of healed erosive esophagitis (up to 12 months).
None Documented
None Documented
Terminal elimination half-life is approximately 1.5 hours. No significant accumulation with once-daily dosing.
Terminal half-life approximately 1.5-2 hours (0.5-1 hour in children); due to short half-life, acid suppression duration is prolonged via irreversible proton pump inhibition
Renal (approx. 70% as metabolites), fecal (approx. 30% as metabolites). Less than 1% excreted unchanged in urine.
Renal (80% as metabolites) and fecal (20%)
Category C
Category C
Proton Pump Inhibitor
Proton Pump Inhibitor